Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma

Marie France Demierre; Josephine Taverna

doi:10.1016/j.jaad.2006.04.025

Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma

Marie France Demierre, Josephine Taverna

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	543-544
Number of pages	2
Journal	Journal of the American Academy of Dermatology
Volume	55
Issue number	3
DOIs	https://doi.org/10.1016/j.jaad.2006.04.025
State	Published - Sep 2006
Externally published	Yes

ASJC Scopus subject areas

Dermatology

Access to Document

10.1016/j.jaad.2006.04.025

Cite this

@article{64b1c5b2f0da4b1b9036188436090ea3,

title = "Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma",

author = "Demierre, \{Marie France\} and Josephine Taverna",

note = "Funding Information: Disclosure: Dr Demierre has a significant interest in the impact of pruritus on patients with cutaneous T-cell lymphoma. In December 2005 she completed a small study of 12 patients, titled “Assessment of Pruritus and Health-related Quality of Life Measures in Patients with Cutaneous T-Cell Lymphoma (CTCL).” This study was sponsored by Merck. Both drugs discussed in this letter are not manufactured by Merck. ",

year = "2006",

month = sep,

doi = "10.1016/j.jaad.2006.04.025",

language = "English (US)",

volume = "55",

pages = "543--544",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma

AU - Demierre, Marie France

AU - Taverna, Josephine

N1 - Funding Information: Disclosure: Dr Demierre has a significant interest in the impact of pruritus on patients with cutaneous T-cell lymphoma. In December 2005 she completed a small study of 12 patients, titled “Assessment of Pruritus and Health-related Quality of Life Measures in Patients with Cutaneous T-Cell Lymphoma (CTCL).” This study was sponsored by Merck. Both drugs discussed in this letter are not manufactured by Merck.

PY - 2006/9

Y1 - 2006/9

UR - https://www.scopus.com/pages/publications/33746924530

UR - https://www.scopus.com/inward/citedby.url?scp=33746924530&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2006.04.025

DO - 10.1016/j.jaad.2006.04.025

M3 - Letter

C2 - 16908377

AN - SCOPUS:33746924530

SN - 0190-9622

VL - 55

SP - 543

EP - 544

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 3

ER -

Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this